Etesevimab Formulation Stability via Histidine Buffer and Surfactants
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Formulating monoclonal antibodies like etesevimab for SARS-CoV-2 that maintain biological activity and stability is challenging due to chemical and physical instability, such as degradation, aggregation, and denaturation, which affects their efficacy and shelf-life.
Innovation Solution
The development of pharmaceutical formulations including etesevimab with a histidine buffer, polyol or tonicity agents like sucrose, and surfactants like polysorbate 80, which help maintain the antibody's conformational integrity and stability for intravenous or subcutaneous administration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If monoclonal antibodies are formulated for pharmaceutical use, then their biological activity and therapeutic efficacy are improved, but their chemical and physical stability deteriorates due to degradation, aggregation, and denaturation
Solution Approach 1:
The patent employs multiple excipients as intermediary substances to protect the monoclonal antibody from degradation. Histidine buffer acts as a pH mediator to maintain chemical stability, while surfactants like polysorbate 80 serve as protective intermediaries that prevent protein aggregation and denaturation. These intermediary substances create a protective environment that allows the antibody to maintain both biological activity and stability simultaneously.
Solution Approach 2:
The formulation creates a composite pharmaceutical system by combining the monoclonal antibody with multiple excipients including buffers, surfactants, and stabilizers. This composite approach allows each component to address specific stability issues - the buffer system maintains pH for chemical stability, while surfactants and other excipients prevent physical degradation through aggregation and denaturation, thereby preserving overall biological activity.
2Duration of action of stationary object
If monoclonal antibodies are stored for extended periods, then their shelf-life is improved, but their biological activity and stability deteriorates due to degradation pathways
Solution Approach 1:
The formulation includes excipients that perform preliminary protective actions before degradation can occur. The histidine buffer is pre-configured to maintain optimal pH levels that prevent deamidation and other chemical degradation. Surfactants are included in advance to prevent aggregation and denaturation pathways. This preliminary protection enables the antibody to maintain biological activity throughout the extended shelf-life.
Solution Approach 2:
The patent employs excipients that provide beforehand cushioning against degradation forces. The buffer system cushions against pH shifts that could trigger degradation, while surfactants cushion against intermolecular forces that lead to aggregation. This prior cushioning mechanism allows the formulation to achieve both extended shelf-life and maintained biological activity.
3Reliability
If protein formulations are designed to maintain conformational integrity, then biological activity is improved, but protection from degradation becomes more difficult
Solution Approach 1:
The formulation employs excipients with multi-functional properties. The histidine buffer not only maintains pH for conformational integrity but also provides buffering capacity against degradation. Surfactants like polysorbate 80 simultaneously prevent aggregation, reduce surface adsorption, and stabilize the protein interface. This multi-functionality approach maintains biological activity without proportionally increasing formulation complexity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulations provide stable and effective solutions for attenuating, preventing, and treating SARS-CoV-2 infection by maintaining the antibody's biological activity and stability, ensuring acceptable shelf-life and in-use stability, and providing a favorable injection site experience.
Implementation Method 1
a histidine buffer
Implementation Method 2
a polyol or tonicity agent
Implementation Method 3
a surfactant
Data Source
AI summary
A pharmaceutical formulation is provided that includes a 2019 novel coronavirus (2019-nCOV) antibody and agents that provide commercially acceptable shelf-life stability, in-use stability and acceptable patient injection site experience. Such formulations can be used for attenuating, preventing and/or treating 2019-nCoV infection or COVID-19.